Crossject (France) Performance
| ALCJ Stock | EUR 1.98 0.01 0.50% |
The firm shows a Beta (market volatility) of 0.56, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Crossject's returns are expected to increase less than the market. However, during the bear market, the loss of holding Crossject is expected to be smaller as well. At this point, Crossject has a negative expected return of -0.17%. Please make sure to confirm Crossject's total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Crossject performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Crossject has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 8.3 M | |
| Total Cashflows From Investing Activities | -6.4 M |
Crossject |
Crossject Relative Risk vs. Return Landscape
If you would invest 229.00 in Crossject on September 24, 2024 and sell it today you would lose (31.00) from holding Crossject or give up 13.54% of portfolio value over 90 days. Crossject is generating negative expected returns and assumes 3.2473% volatility on return distribution over the 90 days horizon. Simply put, 28% of stocks are less volatile than Crossject, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Crossject Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crossject's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Crossject, and traders can use it to determine the average amount a Crossject's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0528
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALCJ |
Estimated Market Risk
| 3.25 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Crossject is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crossject by adding Crossject to a well-diversified portfolio.
Crossject Fundamentals Growth
Crossject Stock prices reflect investors' perceptions of the future prospects and financial health of Crossject, and Crossject fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Crossject Stock performance.
| Return On Equity | -8.32 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (1.74) % | |||
| Operating Margin | (1.95) % | |||
| Current Valuation | 123.81 M | |||
| Shares Outstanding | 34.9 M | |||
| Price To Earning | (4.61) X | |||
| Price To Book | 37.19 X | |||
| Price To Sales | 18.46 X | |||
| Revenue | 912 K | |||
| EBITDA | (6.7 M) | |||
| Cash And Equivalents | 154 K | |||
| Cash Per Share | 0.35 X | |||
| Total Debt | 23.33 M | |||
| Debt To Equity | 105.70 % | |||
| Book Value Per Share | 0.09 X | |||
| Cash Flow From Operations | (6.08 M) | |||
| Earnings Per Share | (0.37) X | |||
| Total Asset | 31.52 M | |||
| Retained Earnings | (19 M) | |||
| Current Asset | 6 M | |||
| Current Liabilities | 1000 K | |||
About Crossject Performance
By analyzing Crossject's fundamental ratios, stakeholders can gain valuable insights into Crossject's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Crossject has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Crossject has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Crossject Socit Anonyme develops needle-free injection systems. The company was founded in 1997 and is based in Dijon, France. CROSSJECT is traded on Paris Stock Exchange in France.Things to note about Crossject performance evaluation
Checking the ongoing alerts about Crossject for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Crossject help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Crossject generated a negative expected return over the last 90 days | |
| Crossject may become a speculative penny stock | |
| Crossject has high historical volatility and very poor performance | |
| Crossject has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 912 K. Net Loss for the year was (10.81 M) with loss before overhead, payroll, taxes, and interest of (205 K). | |
| Crossject has accumulated about 154 K in cash with (6.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. | |
| Roughly 24.0% of the company shares are held by company insiders |
- Analyzing Crossject's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Crossject's stock is overvalued or undervalued compared to its peers.
- Examining Crossject's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Crossject's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Crossject's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Crossject's stock. These opinions can provide insight into Crossject's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Crossject Stock analysis
When running Crossject's price analysis, check to measure Crossject's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crossject is operating at the current time. Most of Crossject's value examination focuses on studying past and present price action to predict the probability of Crossject's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crossject's price. Additionally, you may evaluate how the addition of Crossject to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |